[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
설문조사
스폰서배너광고 안내  배너1 배너2 배너3 배너4
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
유수종
유수종 (Su Jong Yu) 저자 이메일 보기
서울대학교 의과대학, National Institutes of Health
 
조회 405  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma
열기 Authors and Affiliations

Abstract

Background
Cytokine-induced killer (CIK) cell-based immunotherapy is effective as adjuvant therapy in early stage hepatocellular carcinoma (HCC) but lacks efficacy in advanced HCC. We investigated immune suppressor mechanisms focuing on CIKs and myeloid-derived suppressor cells (MDSCs).

Methods
MDSCs were quantified by flow cytometry and quantitative real-time PCR. Cytokines were detected by cytokine array. An LDH cytotoxicity assay was performed in the presence or absence of MDSCs to study CIK function against HCC cells in vitro. An FDA approved PDE5 inhibitor, tadalafil, was used to target MDSCs in vitro and in vivo. Two different murine HCC cell lines were tested in subcutaneous and orthotopic tumor models in C57BL/6 and BALB/c mice. The anti-tumor effects of human CIKs and MDSCs were also tested in vitro.

Results
Adoptive cell transfer of CIKs into tumor bearing mice induced inflammatory mediators (e.g., CX3CL1, IL-13) in the tumor microenvironment and an increase of tumor infiltrating MDSCs leading to impaired anti-tumor activity in two different HCC tumor models. MDSCs efficiently suppressed the cytotoxic activity of CIKs in vitro. In contrast, treatment with a PDE5 inhibitor reversed the MDSC suppressor function via ARG1 and iNOS blockade and systemic treatment with a PDE5 inhibitor prevented MDSC accumulation in the tumor microenvironment upon CIK cell therapy and increased its anti-tumor efficacy. Similar results were observed when human CIKs were tested in vitro in the presence of CD14+HLA-DR-/low MDSCs. Treatment of MDSCs with a PDE5 inhibitor suppressed MDSCs suppressor function and enhanced CIK activity against human HCC cell lines in vitro.

Conclusion
Our results suggest that targeting MDSCs is an efficient strategy to enhance the antitumor efficacy of CIKs for the treatment of patients with HCC.

Lay Summary

CIK cells are a mixture of immune cells given to eliminate cancer cells. However, not all patients respond to this treatment. Here we show in two different liver cancer models that MDSCs are increased in response to CIK cell therapy and subsequently may be targeted with medication to provide an additional therapeutic benefit.

Graphical abstract
Cytokine-induced killer (CIK) cells allow for secretion of cytokines including CX3CL1 and IL-13 which recruit myeloid-derived suppressor cells (MDSCs) to the tumor site. These MDSCs suppress CIK cells lytic function through ARG1 and iNOS dependent manner. Tadalafil, a PDE5 inhibitor, could suppress NDSCs number and fuction simultaneously and augment CIK cells’ anti-tumor effect

Keywords: CIK; PDE5 inhibitor; HCC; immunotherapy; combination therapy

논문정보
- 형식: Research article
- 게재일: 2018년 11월 (BRIC 등록일 2018-11-27)
- 연구진: 국내+국외 연구진
- 분야: Medicine
관련 보도자료
간암 사멸 치료제, 면역억제세포 증가 규명
간암 사멸 치료제, 면역억제세포 증가 규명    사이언스엠디  |  12.07
간암 면역치료제는 면역억제세포를 조절하는 약제와 함께 사용해야 더 효과가 있는 것으로 나타났다. 서울대병원 소화기내과 유수종 교수는 미국 국립암연구소 팀 그레튼 박사와 공동으로 발표한 연구논문 ‘면역억제세포 차단을 통한 간암 면역세...
  댓글 0
등록
 
목록
한국유전체학회
관련링크
유수종 님 전체논문보기 >
관련인물
원재경 (KAIST)
윤정환 (서울대학교 의과대학)
조광현 (KAIST)
황채영 (KAIST)
관련분야 논문보기
Medicine

외부링크
Google (by Su Jong Yu)
Pubmed (by Su Jong Yu)
프리미엄 Bio일정 Bio일정 프리미엄 안내
바이오 QC 실무과정 6기 모집
바이오 QC 실무과정 6기 모집
사전접수: ~2019.01.07
날짜: 2019.03.04~12.09
장소: 성남시 분당구 황새울로 329번길 5
임상시험종사자 생체시료분석법 이해, 생물학적동등성시험의 이해
임상시험종사자 생체시료분석법 이해, 생물학적동등성시험의 이해
사전접수: ~2018.12.20
날짜: 2018.12.20~21
장소: 한국제약바이오협회 강의장 / 이매스교육센터
위로가기
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북    RSS서비스 RSS
에펜도르프코리아